The Effects of Gender-Affirming Hormone Therapy on Biochemical Function in Trans Men Gender-Affirming Hormone Therapy Biochemical Function Renal Function
Conditions
Interventions
Gender-Affirming Hormone Therapy (testosterone enantate)
Experimental Drug
Testosterone enantate
Sponsors
Thammasat university research funds
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Trans Man aged 18-55 years with diagnosis of gender dysphoria based on criteria by Diagnostic and statistical manual of mental disorders 5th edition 2. Never use or did not use any types of hormone at least 6 months before the study starts 3. Consent to be participate in the study
Exclusion criteria
Exclusion criteria: 1. Contraindications to Gender-Affirming Hormone therapy 1.1 Active or previous coronary heart disease or Stroke 1.2 History of venous or arterial thromboembolism 1.3 Diagnosed with severe dyslipidemia or lipid profiles reveal severe abnormalities (LDL > 160 mg/dL, Triglycerides > 500 mg/dL, or Total cholesterol > 200 mg/dL) 1.4 Active or history of liver disease or Lab AST or ALT more than 3 times upper limit normal 1.5 Polycythemia (Hematocrit > 50%) 1.6 Obstructive sleep apnea 1.7 Endometrial or breast cancer 2. Active or history of kidney disease or Serum creatinine > 0.9 mg/dL 3. Received Gender-Affirming hormone therapy or other types of external hormone use in the past 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Creatinine 3 months and 6 months after intervention mg/dL | — |
Secondary
| Measure | Time frame |
|---|---|
| Urine protein to creatinine ratio 3 months and 6 months after intervention times,Percentage muscle mass 3 months and 6 months after intervention percent,Percentage of fat mass 3 months and 6 months after intervention percent | — |
Countries
Thailand
Contacts
Public ContactNonthawat Pasuwattanakul
Thammasat university hospital
Outcome results
None listed